Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes

@article{Davis2007DaptomycinVV,
  title={Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes},
  author={Susan L. Davis and Peggy S. McKinnon and Levi M. Hall and George Delgado and Warren Rose and Robert F. Wilson and Michael Joseph Rybak},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2007},
  volume={27}
}
  • S. DavisP. McKinnon M. Rybak
  • Published 1 December 2007
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Study Objective. To assess the effect of daptomycin compared with vancomycin on the clinical and economic outcomes in patients with complicated skin and skin structure infections. 

The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas

Daptomycin may result in faster clinical improvement than penicillinase‐resistant penicillins or vancomycin for patients with complicated skin and skin structure infections.

Retrospective review of the use of daptomycin for diabetic foot infections.

A retrospective review outlines the clinical outcomes reported for a lipopetide for diabetic foot infections and indicates the need for further research into this drug.

Pharmacological Agents for the Treatment of Skin and Soft Tissue Infections: What is the Role for Daptomycin?

Daptomycin has been shown to achieve good concentrations in skin and soft tissues and is effective and safe for the treatment of SSTIs, compared with other antimicrobial agents.

Pilot Study Comparing Daptomycin And Telavancin In The Treatment Of Skin And Soft Tissue Infections

There did not appear to be any significant difference in clinical outcomes, rapidity of improvement, adverse events nor relapse rates in patients with lower extremity skin and soft tissue infections treated with daptomycin or telavancin.

Daptomycin Versus Other Antimicrobial Agents for the Treatment of Skin and Soft Tissue Infections: A Meta-Analysis

Daptomycin is effective and safe for the treatment of SSTIs and comparisons with new agents, and focusing on proven MRSA S STIs will be helpful for the further evaluation of the drug.

Daptomycin: rationale and role in the management of skin and soft tissue infections.

  • R. Seaton
  • Medicine, Biology
    The Journal of antimicrobial chemotherapy
  • 2008
Clinical experience to date suggests potential economic advantages associated with earlier hospital discharge and shorter duration of therapy, although further detailed cost-effectiveness comparisons are required to validate these observations in different healthcare settings.

Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin

A comprehensive review of the evidence for and experience with daptomycin and its use in SSTIs is presented, finding rapid cidality, good soft tissue penetration, once daily IV bolus administration and activity against resistant Gram-positive infections make d aptomycin an attractive option both in hospitalized and community treated patients.

The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials

This meta-analysis demonstrated that the safety and efficacy of daptomycin was not inferior to that of other first-line drugs, and d aptomycin tended to exhibit superior efficacy when compared with vancomycin or with comparators for SA infections; nevertheless, more high-quality RCTs are needed to draw a more credible conclusion.

Daptomycin for Treatment of complicated skin and skin structure Infections

Daptomycin appears to be a viable alternative to standard treatment options for cSSSI, and the most common side effects were constipation, nausea, and headaches.

An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

The data suggest that physician and patient preference, rather than drug acquisition cost, should be the primary driver of initial antibiotic selection for hospitalized patients with cSSSI.
...

References

SHOWING 1-10 OF 17 REFERENCES

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

The safety and efficacy of daptomycin were comparable with conventional therapy, and the frequency and distribution of adverse events were similar among both treatment groups.

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

  • G. LinaY. Piémont J. Etienne
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1999
Panton-Valentine leukocidin genes were detected in 93% of strains associated with furunculosis and in 85% of those associated with severe necrotic hemorrhagic pneumonia (all community-acquired), and it appears that PVL is mainly associated with nec rotic lesions involving the skin or mucosa.

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.

  • G. PankeyL. Sabath
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
Although bacteriostatic/bactericidal data may provide valuable information on the potential action of antibacterial agents in vitro, it is necessary to combine this information with pharmacokinetic and pharmacodynamic data to provide more meaningful prediction of efficacy in vivo.

The importance of bactericidal drugs: future directions in infectious disease.

  • R. FinbergR. Moellering M. Rybak
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
The bulk of the evidence supports the concept that, in treating endocarditis and meningitis, it is important to use antibacterial agents with in vitro bactericidal activity.

The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges

Evaluating the impact of methicillin resistance in S. aureus bacteremia in patients admitted to the hospital between July 1, 1997, and June 1, 2000 found it was associated with significant increases in length of hospitalization and hospital charges.

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.

  • J. EngemannY. Carmeli K. Kaye
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2003
Methicillin resistance is independently associated with increased mortality and hospital charges among patients with S. aureus SSI and has a greater duration of hospitalization after infection.

Characteristics of Patients With Healthcare-Associated Infection Due to SCCmec Type IV Methicillin-Resistant Staphylococcus aureus

The susceptibility rates among healthcare-associated SCCmec-IV isolates was significantly less for clindamycin, gentamicin, and levofloxacin, indicating that these organisms may quickly acquire resistance to non-β-lactam antibiotics, as do SCCMec-II/III strains.

Epidemiology and Outcomes of Community-Associated Methicillin-Resistant Staphylococcus aureus Infection

In the community setting, the molecular characteristics of the S. aureus strains were heterogeneous and CA-MRSA infections were associated with a more adverse impact on outcome than CA-MSSA infections.

Methicillin-resistant S. aureus infections among patients in the emergency department.

MRSA is the most common identifiable cause of skin and soft-tissue infections among patients presenting to emergency departments in 11 U.S. cities and clinicians should consider obtaining cultures and modifying empirical therapy to provide MRSA coverage.